Many companies are squeezing every last algorithmic drop out of big data to help them make more informed decisions, accessing and analyzing voluminous flows of structured and unstructured market data to guide the optimal allocation of resources. This same promise now beckons for medical research. MSKCC’s Clifford Hudis is quoted.